A Phase 3 interventional study of Andexanet and Placebo in Bleeding, sponsored by Portola Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-08.
Sponsored by Portola Pharmaceuticals (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hemorrhage by AstraZeneca — none open to participants now, none under way, none of them phase 3. Hemorrhage · AstraZeneca.
Among the 12 studies in Hemorrhage by AstraZeneca, this one is one of 2 that started in 2014, is one of 4 in phase 3, and was the 4th registered.
1,384 studies on the registry are indexed under Hemorrhage; 245 are open to participants now.
Browse Hemorrhage studies →None of the 12 studies in Hemorrhage by AstraZeneca is open now. The open studies under Hemorrhage, anywhere →
Of the 171 Hemorrhage studies recruiting now, 109 (64%) set no upper age limit and 41 (24%) stop at 75 or younger; 26 take children under 18; 21 take healthy volunteers.
This study: 50 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is below the median of 102 across 927 interventional studies indexed under Hemorrhage.
Median enrollment 131 across the 8 interventional studies, 1,359 across the 4 observational. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Portola Pharmaceuticals, one of the names counted as AstraZeneca. Under that name alone:
Portola Pharmaceuticals is the lead sponsor of 23 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Hemorrhage by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this stuy is to evaluate the ability of Andexanet Alfa to reverse the anticoagulation effect of Apixaban.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Andexanet (antidote)
Biological: Andexanet
Placebo
Other: Placebo
Efficacy: Percent Change From Baseline in Anti-fXa Activity at the Nadir (Parts I and II)
In Part I, the primary endpoint was percent change from baseline in anti-fXa activity at the nadir, when nadir was defined as the smaller value for anti-fXa activity at the +2 minutes or +5 minutes time point following the end of the bolus. In Part II, the primary endpoint was the percent change from baseline in anti-fXa activity from its baseline to nadir, when nadir was defined as the smaller value for anti-fXa activity between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion. The baseline for the primary endpoint in both parts was the anti-fXa activity just prior to administration of andexanet, 3 hours following the Day 4 dose of apixaban. Anti-fXa activity was measured by a modified chromogenic assay.
Time frame: Baseline to +2 minutes or +5 minutes following the end of andexanet/placebo bolus (Part I), or 10 minutes prior to end of andexanet/placebo continuous infusion or 5 minutes after the end of andexanet/placebo continuous infusion (Part II)
Efficacy: Percent Change From Baseline in Anti-fXa Activity at the Nadir (Part II)
The percent change from baseline in anti-fXa activity at the nadir, following the bolus, when nadir was defined as the smaller value for anti-fXa activity at the +2 minute or +5 minute time point after the completion of the andexanet bolus (Part II). Baseline was the last assessment obtained prior to the first dose of andexanet or placebo
Time frame: Baseline to +2 minutes or +5 minutes following the end of andexanet/placebo bolus (Part II)
Efficacy: Number of Participants With ≥80% Reduction in the Anti-fXa Activity From Baseline to Nadir
Occurrence of ≥80% reduction in anti-fXa activity from its baseline to nadir, when nadir was defined as the smaller value for anti-fXa activity at the +2 minute or +5 minute time point after the completion of the andexanet bolus (Part I) or between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion (inclusive) \[Part II\]. Baseline was the last assessment obtained prior to the first dose of andexanet or placebo
Time frame: Baseline to +2 minutes or +5 minutes following the end of andexanet/placebo bolus (Part I), or 10 minutes prior to end of andexanet/placebo continuous infusion or 5 minutes after the end of andexanet/placebo continuous infusion (Part II)
Efficacy -Change From Baseline in Free Apixaban Concentration at the Nadir
Change from baseline in free apixaban concentration (ng/mL) at the nadir, when nadir was defined as the smaller value for free apixaban at the +2 minute or +5 minute time point after the completion of the andexanet bolus (Part I) or between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion (inclusive) \[Part II\]. Free plasma concentrations of apixaban was determined using a validated method that involved analysis of citrated human plasma with high-throughput equilibrium dialysis followed by liquid chromatography mass spectrometry.
Time frame: Baseline to +2 minutes or +5 minutes following the end of andexanet/placebo bolus (Part I), or 10 minutes prior to end of andexanet/placebo continuous infusion or 5 minutes after the end of andexanet/placebo continuous infusion (Part II)
Efficacy: Change in Thrombin Generation (ETP) From Baseline to Its Peak [Parts I and II]
Change in ETP from baseline to its peak, where peak was defined as the largest value for ETP between the +2 minute time point and the +10 minute time point after the end of the andexanet bolus (inclusive) {Part I\] or between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion (inclusive) \[Part II\]. Baseline was the last assessment obtained prior to the first dose of andexanet or placebo. ETP was measured using a tissue factor-initiated thrombin generation assay.
Time frame: Baseline to +2 minutes or +10 minutes following the end of andexanet/placebo bolus (Part I), or 10 minutes prior to end of andexanet/placebo continuous infusion or 5 minutes after the end of andexanet/placebo continuous infusion (Part II)
Efficacy: Number of Participants With Thrombin Generation (ETP) Above the Lower Limit of the Derived Normal Range at Its Peak (mITT Population)
Number of participants with ETP above the lower limit of the normal range at its peak, between the +2 minute time point and the +10 minute time point after the end of the andexanet bolus (inclusive) \[Part I\] or between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion (inclusive) \[Part II\]. ETP was measured using a tissue factor-initiated thrombin generation assay
Time frame: Baseline to +2 minutes or +10 minutes following the end of andexanet/placebo bolus (Part I), or 10 minutes prior to end of andexanet/placebo continuous infusion or 5 minutes after the end of andexanet/placebo continuous infusion (Part II)
Subject recruitment occurred at investigative site in the US between March 2014 through December 2014
| Milestone | Placebo (Part I) | Andexanet (Part I) | Placebo (Part II) | Andexanet (Part II) |
|---|---|---|---|---|
| Started | 9 | 25 | 9 | 25 |
| Completed | 9 | 24 | 8 | 24 |
| Not completed | 0 | 1 | 1 | 1 |
| Withdrew: Did not receive treatment | 0 | 1 | 1 | 1 |
In Part I, the primary endpoint was percent change from baseline in anti-fXa activity at the nadir, when nadir was defined as the smaller value for anti-fXa activity at the +2 minutes or +5 minutes time point following the end of the bolus. In Part II, the primary endpoint was the percent change from baseline in anti-fXa activity from its baseline to nadir, when nadir was defined as the smaller value for anti-fXa activity between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion. The baseline for the primary endpoint in both parts was the anti-fXa activity just prior to administration of andexanet, 3 hours following the Day 4 dose of apixaban. Anti-fXa activity was measured by a modified chromogenic assay.
| Percent change in anti-fXa activity | Placebo (Part I) | Andexanet (Part I) | Placebo (Part II) | Andexanet (Part II) |
|---|---|---|---|---|
| Efficacy: Percent Change From Baseline in Anti-fXa Activity at the Nadir (Parts I and II) | -20.71 ± 8.559 | -93.86 ± 1.650 | -32.70 ± 5.578 | -92.34 ± 2.809 |
The percent change from baseline in anti-fXa activity at the nadir, following the bolus, when nadir was defined as the smaller value for anti-fXa activity at the +2 minute or +5 minute time point after the completion of the andexanet bolus (Part II). Baseline was the last assessment obtained prior to the first dose of andexanet or placebo
| Percent change in anti-fXa activity | Placebo (Part II) | Andexanet (Part II) |
|---|---|---|
| Efficacy: Percent Change From Baseline in Anti-fXa Activity at the Nadir (Part II) | -16.73 ± 4.104 | -93.49 ± 1.525 |
Occurrence of ≥80% reduction in anti-fXa activity from its baseline to nadir, when nadir was defined as the smaller value for anti-fXa activity at the +2 minute or +5 minute time point after the completion of the andexanet bolus (Part I) or between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion (inclusive) \[Part II\]. Baseline was the last assessment obtained prior to the first dose of andexanet or placebo
| Participants | Placebo (Part I) | Andexanet (Part I) | Placebo (Part II) | Andexanet (Part II) |
|---|---|---|---|---|
| Efficacy: Number of Participants With ≥80% Reduction in the Anti-fXa Activity From Baseline to Nadir | 0 | 24 | 0 | 23 |
Change from baseline in free apixaban concentration (ng/mL) at the nadir, when nadir was defined as the smaller value for free apixaban at the +2 minute or +5 minute time point after the completion of the andexanet bolus (Part I) or between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion (inclusive) \[Part II\]. Free plasma concentrations of apixaban was determined using a validated method that involved analysis of citrated human plasma with high-throughput equilibrium dialysis followed by liquid chromatography mass spectrometry.
| ng/mL | Placebo (Part I) | Andexanet (Part I) | Placebo (Part II) | Andexanet (Part II) |
|---|---|---|---|---|
| Efficacy -Change From Baseline in Free Apixaban Concentration at the Nadir | -1.854 ± 1.6152 | -9.338 ± 3.2043 | -2.964 ± 1.1567 | -6.480 ± 2.7814 |
Change in ETP from baseline to its peak, where peak was defined as the largest value for ETP between the +2 minute time point and the +10 minute time point after the end of the andexanet bolus (inclusive) {Part I\] or between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion (inclusive) \[Part II\]. Baseline was the last assessment obtained prior to the first dose of andexanet or placebo. ETP was measured using a tissue factor-initiated thrombin generation assay.
| nmol/min | Placebo (Part I) | Andexanet (Part I) | Placebo (Part II) | Andexanet (Part II) |
|---|---|---|---|---|
| Efficacy: Change in Thrombin Generation (ETP) From Baseline to Its Peak [Parts I and II] | 88.182 ± 125.7621 | 1323.180 ± 335.4321 | 189.409 ± 184.7842 | 1193.060 ± 263.3471 |
Number of participants with ETP above the lower limit of the normal range at its peak, between the +2 minute time point and the +10 minute time point after the end of the andexanet bolus (inclusive) \[Part I\] or between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion (inclusive) \[Part II\]. ETP was measured using a tissue factor-initiated thrombin generation assay
| Participants | Placebo (Part I) | Andexanet (Part I) | Placebo (Part II) | Andexanet (Part II) |
|---|---|---|---|---|
| Efficacy: Number of Participants With Thrombin Generation (ETP) Above the Lower Limit of the Derived Normal Range at Its Peak (mITT Population) | 1 | 24 | 2 | 23 |
Collected over ~8 to 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Part I) | — | 0/9 (0%) | 3/9 (33.3%) |
| Andexanet (Part I) | — | 0/24 (0%) | 7/24 (29.2%) |
| Placebo (Part II) | — | 0/8 (0%) | 2/8 (25%) |
| Andexanet (Part II) | — | 0/24 (0%) | 9/24 (37.5%) |
| Event | Placebo (Part I) | Andexanet (Part I) | Placebo (Part II) | Andexanet (Part II) |
|---|---|---|---|---|
| Infusion Related ReactionInjury, poisoning and procedural complications | 0/9 | 3/24 | 2/8 | 4/24 |
| Vessel Puncture Site HaemorrhageGeneral disorders | 1/9 | 0/24 | 0/8 | 4/24 |
| HeadacheNervous system disorders | 1/9 | 3/24 | 0/8 | 0/24 |
| Dermatitis ContactSkin and subcutaneous tissue disorders | 1/9 | 3/24 | 1/8 | 0/24 |
| Vessel Puncture Site PainGeneral disorders | 1/9 | 2/24 | 0/8 | 0/24 |
| ConstipationGastrointestinal disorders | 0/9 | 0/24 | 0/8 | 2/24 |
| Vessel Puncture Site SwellingGeneral disorders | 0/9 | 0/24 | 0/8 | 2/24 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/9 | 2/24 | 0/8 | 0/24 |
33 and 32 subjects were randomized in Part I and Part II of study, respectively
| Age, Continuous(years) | Placebo (Part I) | Andexanet (Part I) | Placebo (Part II) | Andexanet (Part II) | Total |
|---|---|---|---|---|---|
| Mean | 59.0 ± 3.54 | 61.0 ± 6.37 | 59.5 ± 6.91 | 59.4 ± 7.83 | 59.9 ± 6.64 |
| Sex: Female, Male(Participants) | Placebo (Part I) | Andexanet (Part I) | Placebo (Part II) | Andexanet (Part II) | Total |
|---|---|---|---|---|---|
| Female | 3 | 11 | 3 | 7 | 24 |
| Male | 6 | 13 | 5 | 17 | 41 |
The record gives a start of Mar 2014, a primary completion of Apr 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2018, 3 years 5 months after primary completion. A results delay was requested in Sep 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PRT064445